Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease

Gianna Camiciottoli, Francesca Bigazzi, Chiara Magni, Viola Bonti, Stefano Diciotti, Maurizio Bartolucci, Mario Mascalchi, Massimo Pistolesi, Gianna Camiciottoli, Francesca Bigazzi, Chiara Magni, Viola Bonti, Stefano Diciotti, Maurizio Bartolucci, Mario Mascalchi, Massimo Pistolesi

Abstract

Background: In addition to lung involvement, several other diseases and syndromes coexist in patients with chronic obstructive pulmonary disease (COPD). Our purpose was to investigate the prevalence of idiopathic arterial hypertension (IAH), ischemic heart disease, heart failure, peripheral vascular disease (PVD), diabetes, osteoporosis, and anxious depressive syndrome in a clinical setting of COPD outpatients whose phenotypes (predominant airway disease and predominant emphysema) and severity (mild and severe diseases) were determined by clinical and functional parameters.

Methods: A total of 412 outpatients with COPD were assigned either a predominant airway disease or a predominant emphysema phenotype of mild or severe degree according to predictive models based on pulmonary functions (forced expiratory volume in 1 second/vital capacity; total lung capacity %; functional residual capacity %; and diffusing capacity of lung for carbon monoxide %) and sputum characteristics. Comorbidities were assessed by objective medical records.

Results: Eighty-four percent of patients suffered from at least one comorbidity and 75% from at least one cardiovascular comorbidity, with IAH and PVD being the most prevalent ones (62% and 28%, respectively). IAH prevailed significantly in predominant airway disease, osteoporosis prevailed significantly in predominant emphysema, and ischemic heart disease and PVD prevailed in mild COPD. All cardiovascular comorbidities prevailed significantly in predominant airway phenotype of COPD and mild COPD severity.

Conclusion: Specific comorbidities prevail in different phenotypes of COPD; this fact may be relevant to identify patients at risk for specific, phenotype-related comorbidities. The highest prevalence of comorbidities in patients with mild disease indicates that these patients should be investigated for coexisting diseases or syndromes even in the less severe, pauci-symptomatic stages of COPD. The simple method employed to phenotype and score COPD allows these results to be translated easily into daily clinical practice.

Keywords: COPD phenotypes; COPD severity; comorbidities.

Figures

Figure 1
Figure 1
Prevalence of comorbidities in 412 outpatients with COPD. Abbreviations: ADS, anxious depressive syndrome; com, comorbidities; COPD, chronic obstructive pulmonary disease; D, diabetes; HF, heart failure; IAH, idiopathic arterial hypertension; IHD, ischemic heart disease; O, osteoporosis; PVD, peripheral vascular disease.
Figure 2
Figure 2
Prevalence of comorbidities in 222 patients with the predominant airway disease (A) phenotype and in 190 patients with the predominant emphysema phenotype (B). Abbreviations: ADS, anxious depressive syndrome; com, comorbidities; D, diabetes; HF, heart failure; IAH, idiopathic arterial hypertension; IHD, ischemic heart disease; O, osteoporosis; PVD, peripheral vascular disease.
Figure 3
Figure 3
Comparisons of the prevalence of each examined comorbidity in 222 patients with a predominant airway disease phenotype and in 190 patients with a predominant emphysema phenotype. Note:*P<0.05. Abbreviations: ADS, anxious depressive syndrome; com, comorbidities; D, diabetes; HF, heart failure; IAH, idiopathic arterial hypertension; IHD, ischemic heart disease; O, osteoporosis; PVD, peripheral vascular disease.
Figure 4
Figure 4
Prevalence of comorbidities in 412 outpatients according to mild or severe grade of COPD. Notes:*P<0.05; ***P<0.0001. Abbreviations: ADS, anxious depressive syndrome; com, comorbidities; COPD, chronic obstructive pulmonary disease; D, diabetes; HF, heart failure; IAH, idiopathic arterial hypertension; IHD, ischemic heart disease; O, osteoporosis; PVD, peripheral vascular disease.
Figure 5
Figure 5
Prevalence of cardiovascular comorbidities in 412 outpatients according to mild or severe grade of COPD and according to the predominant phenotype. Notes:*P<0.05; ***P<0.0001. Abbreviation: COPD, chronic obstructive pulmonary disease.

References

    1. Paoletti M, Camiciottoli G, Meoni E, et al. Explorative data analysis techniques and unsupervised clustering methods to support clinical assessment of chronic obstructive pulmonary disease (COPD) phenotypes. J Biomed Inform. 2009;42(6):1013–1021.
    1. Camiciottoli G, Bigazzi F, Paoletti M, Cestelli L, Lavorini F, Pistolesi M. Pulmonary function and sputum characteristics predict computed tomography phenotype and severity of COPD. Eur Respir J. 2013;42(3):626–635.
    1. Burgel PR, Paillasseur JL, Roche N. Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities. Biomed Res Int. 2014:420134.
    1. Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J. 2009;34(4):812–818.
    1. Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax. 2008;63(9):761–767.
    1. Agustí A, Edwards LD, Rennard SI, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483.
    1. Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(2):347–360.
    1. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–580.
    1. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):258–266.
    1. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(12):1259–1265.
    1. Maclay JD, McAllister DA, Mills NL, et al. Vascular Dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(6):513–520.
    1. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005;82(1):53–59.
    1. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med. 2007;175(5):458–463.
    1. Mannino DM, Higuchi K, Yu TC, et al. Economic burden of COPD in the presence of comorbidities. Chest. 2015;148(1):138–150.
    1. Gershon AS, Mecredy GC, Guan J, Victor JC, Goldstein R, To T. Quantifying comorbidity in individuals with COPD: a population study. Eur Respir J. 2015;45(1):51–59.
    1. Wacker ME, Jörres RA, Schulz H, et al. for COSYCONET-consortium Direct and indirect costs of COPD and its comorbidities: results from the German COSYCONET study. Respir Med. 2016;111:39–46.
    1. Tsiligianni IG, Kosmas E, Van der Molen T, Tzanakis N. Managing comorbidity in COPD: a difficult task. Curr Drug Targets. 2013;14(2):158–176.
    1. Anecchino C, Rossi E, Fanizza C, De Rosa M, Tognoni G, Romero M, Working Group ARNO project Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population. Int J Chron Obstruct Pulmon Dis. 2007;2(4):567–574.
    1. Sode BF, Dahl M, Nordestgaard BG. Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish Nationwide Study of 7.4 million individuals. Eur Heart J. 2011;32(19):2365–2375.
    1. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(11):956–962.
    1. Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med. 2015;10(1):24.
    1. Mahboub B, Alzaabi A, Iqbal MN, et al. Comorbidities associated with COPD in the Middle East and North Africa region: association with severity and exacerbations. Int J Chron Obstruct Pulmon Dis. 2016;11:273–280.
    1. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–968.
    1. Watz H, Waschki B, Kirsten A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest. 2009;136(4):1039–1046.
    1. Poulain M, Doucet M, Drapeau V, et al. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease. Chron Respir Dis. 2008;5(1):35–41.
    1. Song D, Fang G, Greenberg H, Liu SF. Chronic intermittent hypoxia exposure-induced atherosclerosis: a brief review. Immunol Res. 2015;63(1–3):121–130.
    1. Bernardo I, Bozinovski S, Vlahos R. Targeting oxidant dependent mechanisms for the treatment of COPD and its comorbidities. Pharmacol Ther. 2015;155:60–79.
    1. Okur HK, Pelin Z, Yuksel M, Yosunkaya S. Lipid peroxidation and paraoxonase activity in nocturnal cyclic and sustained intermittent hypoxia. Sleep Breath. 2013;17(1):365–371.
    1. McNicholas W, Verbraecken J, Marin JM. Sleep disorders in COPD: the forgotten dimension. Eur Respir Rev. 2013;22(129):365–375.
    1. Jebouck A, Boonen S, Decramer M, Janssens W. COPD, bone metabolism and osteoporosis. Chest. 2011;139(3):648–657.
    1. Lind B, Feng Y. The association of low bone mineral density with systemic inflammation in clinically stable COPD. Endocrine. 2012;42(1):190–195.
    1. Kiyokawa H, Muro S, Oguma T, et al. Impact of COPD exacerbations on osteoporosis assessed by chest CT scan. COPD. 2012;9(3):235–242.
    1. Mineo TC, Ambrogi V, Mineo D, Fabbri A, Fabbrini E, Massoud R. Bone mineral density improvement after lung volume reduction surgery for severe emphysema. Chest. 2005;127(6):1960–1966.
    1. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–969.
    1. Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax. 2008;63(7):599–605.
    1. Methvin JN, Mannino DM, Casey BR. COPD prevalence in Southeastern Kentucky: the burden of lung disease study. Chest. 2009;135(1):102–107.
    1. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–735.
    1. Celli BR. Recommendation for the early diagnosis of COPD: The AIMAR view. Multidiscip Respir Med. 2015;10(1):6.
    1. Welte T, Vogelmeier C, Papi A. COPD: early diagnosis and treatment to slow disease progression. Int J Clin Pract. 2015;69(3):336–349.
    1. Brown JP, Martinez CH. Chronic obstructive pulmonary disease comorbidities. Curr Opin Pulm Med. 2016;22(2):113–118.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner